


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.


1. (Canceled)

2. (Currently amended) A compound ~~The compound of claim 1,~~ having the structure of Formula I:




wherein R is lower alkyl or halo and n is 0-5, or a pharmaceutically acceptable salt thereof.

3. (Currently amended) A compound ~~The compound of claim 1,~~ having the structure of Formula II:




wherein R is lower alkyl, or a pharmaceutically acceptable salt thereof.

4. (Currently amended) A compound ~~The compound of claim 1,~~ having the structure of Formula III:



wherein R is lower alkyl, or a pharmaceutically acceptable salt thereof.

5. (Currently amended) A compound ~~The compound of claim 1,~~ having the structure of Formula IV:



wherein R^a and R^b are each independently hydrogen, lower alkyl or halo, n is 1-5, and V is (CH₂)_n, CONH, or CONHCH₂, or a pharmaceutically acceptable salt thereof.

6. (Currently amended) A pharmaceutical composition comprising a compound of any one of claims 2-5 ~~claim 1~~ and a pharmaceutically acceptable carrier.

7. (Currently amended) A method of treating a hyperproliferative disease or cancer in an animal, comprising administering to said animal a therapeutically effective amount of a compound of any one of claims 2-5 ~~claim 1~~.

8. (Original) The method of claim 7, further comprising administering an inducer of apoptosis.

9. (Original) The method of claim 8, wherein said inducer of apoptosis is a chemotherapeutic agent.

10. (Original) The method of claim 9, wherein said chemotherapeutic agent is embelin.

11. (Original) The method of claim 8, wherein said inducer of apoptosis is radiation.

12. (Currently amended) The method of claim 8, wherein said compound of ~~claim 1~~ is administered prior to said inducer of apoptosis.

13. (Currently amended) The method of claim 8, wherein said compound of ~~claim 1~~ is administered concurrently with said inducer of apoptosis.

14. (Currently amended) The method of claim 8, wherein said compound of ~~claim 1~~ is administered after said inducer of apoptosis.

15. (Currently amended) A method of inducing apoptosis in a cell comprising contacting said cell with a compound of any one of claims 2-5 ~~claim 1~~.

16. (Currently amended) A method of rendering a cell sensitive to an inducer of apoptosis comprising contacting said cell with a compound of any one of claims 2-5 ~~claim 1~~.

17. (Original) The method of claim 16, further comprising contacting said cell with an inducer of apoptosis.

18-19. (Canceled)

20. (Currently amended) A kit comprising a compound of any one of claims 2-5 ~~claim 1~~ and instructions for administering said compound to an animal.

21. (Original) The kit of claim 20, further comprising an inducer of apoptosis.

22. (Original) The kit of claim 21, wherein said inducer of apoptosis is a chemotherapeutic agent.

23. (Original) The kit of claim 22, wherein said chemotherapeutic agent is embelin.

24. (Original) The kit of claim 20, wherein said instructions are for administering said compound to an animal having a hyperproliferative disease.

25. (Original) The kit of claim 24, wherein said hyperproliferative disease is cancer.